Targeting the Hippo pathway: Clinical implications and therapeutics

Shuai Ye; T S Karin Eisinger-Mathason

doi:10.1016/j.phrs.2015.11.025

Targeting the Hippo pathway: Clinical implications and therapeutics

Pharmacol Res. 2016 Jan:103:270-8. doi: 10.1016/j.phrs.2015.11.025. Epub 2015 Dec 8.

Authors

Shuai Ye¹, T S Karin Eisinger-Mathason²

Affiliations

¹ Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA; University of Pennsylvania Sarcoma Program, Philadelphia, PA, USA.
² Abramson Family Cancer Research Institute, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, USA; Department of Pathology and Laboratory Medicine, Philadelphia, PA, USA; University of Pennsylvania Sarcoma Program, Philadelphia, PA, USA. Electronic address: karineis@mail.med.upenn.edu.

PMID: 26678601
DOI: 10.1016/j.phrs.2015.11.025

Abstract

The Hippo pathway plays a critical role in tissue and organ size regulation by restraining cell proliferation and apoptosis under homeostatic conditions. Deregulation of this pathway can promote tumorigenesis in multiple malignant human tumor types, including sarcoma, breast, lung and liver cancers. In this review, we summarize the current understanding of Hippo pathway function, it's role in human cancer, and address the potential of Hippo pathway member proteins as therapeutic targets for a variety of tumors.

Keywords: Cancer; Hippo; YAP.

Publication types

Review

MeSH terms

Adaptor Proteins, Signal Transducing / metabolism
Animals
Hippo Signaling Pathway
Humans
Neoplasms / drug therapy
Neoplasms / metabolism
Phosphoproteins / metabolism
Protein Serine-Threonine Kinases / metabolism*
Signal Transduction
Transcription Factors
YAP-Signaling Proteins

Substances

Adaptor Proteins, Signal Transducing
Phosphoproteins
Transcription Factors
YAP-Signaling Proteins
YAP1 protein, human
Protein Serine-Threonine Kinases